Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Professionals Inc

Neither a doctor nor a teaching hospital

Research payments

$1,784,255

263 payments

Through program year 2025, Clinical Research Professionals Inc is reported as receiving $1,784,255 in research payments, across 263 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $177,003 75
2024 Research $77,694 26
2023 Research $32,806 16
2022 Research $177,108 31
2021 Research $359,171 41
2020 Research $595,916 55
2019 Research $364,558 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $810,356 56 payments
  2. H. Lundbeck A S $238,142 87 payments
  3. Novartis Pharmaceuticals Corporation $198,852 3 payments
  4. Vanda Pharmaceuticals Inc. $192,551 67 payments
  5. Allergan Inc. $164,031 25 payments
  6. Celgene Corporation $69,201 4 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $52,898 15 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $33,432 2 payments
  9. ACADIA Pharmaceuticals Inc $18,050 1 payment
  10. Biohaven Pharmaceuticals, Inc. $6,742 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $663,209 39 payments
  2. Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding Trial of Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments $238,142 87 payments
  3. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $149,342 17 payments
  4. A 12Week Phase 2A Randomized Doubleblind Sponsoropen Placebocontrolled Parallel Group Study to Assess the Safety Tolerability and Pharmacodynamics of Pf06882961 Titration in Adults With Type 2 Diabetes Mellitus Treated With Metformin and in Nondiabetic Adults With Obesity $139,397 15 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $138,691 36 payments
  6. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (Ljn452) & Licogliflozin (Lik066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalco $106,027 2 payments
  7. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (Ljn452) & Licogliflozin (Lik066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (Nash) and Liver Fibrosis $92,825 1 payment
  8. PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) $61,259 2 payments
  9. A Phase 2 Double Blind Placebo Controlled Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia $59,640 18 payments
  10. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $33,432 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record